Loading...
Ascendis Pharma A/S
ASND•NASDAQ
HealthcareBiotechnology
$173.06
$-4.49(-2.53%)
Ascendis Pharma A/S (ASND) Financial Performance & Statements
Review Ascendis Pharma A/S’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
36.34%
↑ 36.34%
Operating Income Growth
38.81%
↑ 38.81%
Net Income Growth
21.47%
↑ 21.47%
Operating Cash Flow Growth
34.48%
↑ 34.48%
Operating Margin
-90.54%
↓ 90.54%
Gross Margin
85.30%
↑ 85.30%
Net Profit Margin
-92.67%
↓ 92.67%
ROE
191.42%
↑ 191.42%
ROIC
-189.75%
↓ 189.75%
Ascendis Pharma A/S (ASND) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Ascendis Pharma A/S stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $173.92M | $57.83M | $36.00M | $95.89M |
| Cost of Revenue | $14.02M | $11.20M | $11.46M | $7.57M |
| Gross Profit | $159.89M | $46.63M | $24.53M | $88.33M |
| Gross Profit Ratio | $0.92 | $0.81 | $0.68 | $0.92 |
| R&D Expenses | $79.30M | $73.54M | $83.48M | $70.69M |
| SG&A Expenses | $78.78M | $68.13M | $74.31M | $66.78M |
| Operating Expenses | $159.51M | $143.38M | $157.79M | $137.47M |
| Total Costs & Expenses | $173.53M | $154.58M | $169.25M | $145.04M |
| Interest Income | $0.00 | $28.28M | $49.05M | $3.58M |
| Interest Expense | $0.00 | $25.35M | $19.62M | $77.16M |
| Depreciation & Amortization | $4.47M | $1.70M | $2.02M | $4.50M |
| EBITDA | -$37.89M | -$71.13M | -$87.51M | -$46.89M |
| EBITDA Ratio | -$0.22 | -$1.23 | -$2.43 | -$0.49 |
| Operating Income | $383000.00 | -$96.74M | -$133.26M | -$49.15M |
| Operating Income Ratio | $0.002 | -$1.67 | -$3.70 | -$0.51 |
| Other Income/Expenses (Net) | -$37.77M | -$1.44M | $24.11M | -$79.38M |
| Income Before Tax | -$37.38M | -$98.18M | -$109.15M | -$128.53M |
| Income Before Tax Ratio | -$0.21 | -$1.70 | -$3.03 | -$1.34 |
| Income Tax Expense | $1.08M | $1.02M | $229000.00 | $2.51M |
| Net Income | -$38.47M | -$99.20M | -$109.38M | -$131.03M |
| Net Income Ratio | -$0.22 | -$1.72 | -$3.04 | -$1.37 |
| EPS | -$0.64 | $0.00 | -$1.91 | -$2.30 |
| Diluted EPS | -$0.64 | $0.00 | -$1.91 | -$2.30 |
| Weighted Avg Shares Outstanding | $59.79M | $0.00 | $57.35M | $56.88M |
| Weighted Avg Shares Outstanding (Diluted) | $59.79M | $0.00 | $57.35M | $56.88M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan